Adiponectin in Obese Women With T2DN and Effects by RAS Blocker
Information source: Shanghai Jiao Tong University of Medicine
Information obtained from ClinicalTrials.gov on March 21, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Obese; Type 2 Diabetes; Diabetic Nephropathy; Glucose Metabolism; Angiotensin II Type 1 Receptor Blockers
Intervention: losartan (Drug)
Phase: N/A
Status: Completed
Sponsored by: Shanghai Jiao Tong University of Medicine Official(s) and/or principal investigator(s):
hui min Jin, MD, Principal Investigator, Affiliation: shanghai No 3 people's hospital
Summary
Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and
is the prominent feature of the metabolic syndrome. Adiponectin plays an important part in
glucose metabolism,insulin resistance, the deterioration of renal function. we hypothesize
there is a difference serum adiponectin levels between obese and non-obese women with type 2
diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs
blocker(Losartan).
Clinical Details
Official title: Adiponectin in Obese Women With T2DN and Effects by RAS Blocker
Study design: Treatment, Open Label, Parallel Assignment, Safety/Efficacy Study
Primary outcome: GFR, HbA1c and the adiponectin concentration.
Detailed description:
it would be a prospective cohort study. According to BMI, all the women, aged>30yr, diagnosed
type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided
to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index(
fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and
recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg
daily, 6 month). during the study, the above mentioned parameters will also be recorded 3
month intervals. Meanwhile, any side effects would be pay attention.
Eligibility
Minimum age: 30 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Type 2 diabetic nephropathy
- CKD at stage 1~4
Exclusion Criteria:
- Type 1 diabetes or nondiabetic renal disease
- An elevated plasma K level.
Locations and Contacts
Additional Information
Starting date: April 2007
Ending date: October 2007
Last updated: November 20, 2007
|
